Related Experiment Videos
HIV pharmacogenomics: closer to personalized therapy?
Deborah A Payne1, Barbara J Bryant,
1Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555-0743, USA. dpayne@utmb.edu
American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice
|June 4, 2004
Summary
Pharmacogenomic testing, including HIV and mitochondrial DNA, helps predict and manage adverse drug reactions in patients on antiretroviral therapy. This approach improves treatment efficacy and patient outcomes for complex, long-term regimens.
Area of Science:
- Pharmacogenomics and Molecular Diagnostics
- Infectious Disease Therapeutics
- Clinical Pharmacology
Background:
- Adverse drug reactions (ADRs) encompass unintended effects and loss of efficacy in antiretroviral therapy (ART).
- Traditional pharmacogenomics focuses on host nuclear DNA, but ART challenges necessitate broader genetic analysis.
- Extranuclear genetic material, including HIV and mitochondrial genomes, plays a role in ART outcomes.
Purpose of the Study:
- To explore the expanded role of pharmacogenomic testing in managing antiretroviral therapy (ART).
- To highlight molecular assays for characterizing host and pathogen genetic material.
- To demonstrate the clinical utility of pharmacogenomic testing for improving ART efficacy and patient outcomes.
Main Methods:
- Utilizing molecular assays to analyze host nuclear DNA, HIV genomes, and mitochondrial genomes.
- Implementing high-resolution resistance testing (phenotypic, genotypic, virtual phenotypic) to detect loss of therapeutic efficacy.
- Applying complex technical and interpretative methods for resistance assays.
Main Results:
- Pharmacogenomic testing, incorporating extranuclear genetic material, effectively addresses antiretroviral-associated ADRs.
- Resistance assays demonstrate significant utility in optimizing ART for patients requiring lifelong treatment.
- These methods improve therapeutic efficacy in complex and sustained antiretroviral regimens.
Conclusions:
- Pharmacogenomic testing provides a proof of principle for clinical application in HIV-positive patients.
- Expanded pharmacogenomic assays can improve outcomes for patients on complex and sustained drug regimens.
- Future applications include predicting drug toxicity and disease progression through genetic analysis.